The FDA has approved a first-of-its-kind treatment for dry age-related macular degeneration, a leading cause of blindness in adults over 55. Developed by LumiThera Inc., the device showed ...

DelveInsight's 'Dry Age-Related Macular Degeneration Pipeline Insight 2025' report provides comprehensive global coverage of ...

A multidisciplinary team of researchers from the Istituto Italiano di Tecnologia (IIT-Italian Institute of Technology) and ...

Dry Age-Related Macular Degeneration Market The healthcare landscape in 2025 is poised for a transformative shift, driven by innovation and ...

PST-611-CT1 is a first-in-human single ascending dose trial aiming to confirm the favorable safety profile of the drug and validate the maximal dose for the Phase II proof-of-concept study, in six to ...

The phase 1 clinical trial is a multicenter, open-label, dose-escalation study to assess drug safety via intravitreal ...

Dame Judi Dench has given an update on her failing eyesight due to macular disease, admitting that she can no longer leave ...

Age-related macular degeneration may cause a gradual reduction in your central vision over time, so you might not recognize AMD at first.

Regenxbio's rolling BLA submission completion of RGX-121 for the treatment of patients with MPS II expected in Q1 of 2025.

Izervay (avacincaptad pegol) is a prescription injection used to treat severe age-related macular degeneration ... severe vision loss than dry AMD. During Izervay treatment, your doctor will ...

On completion of the scans and tests, he said: “You have early age-related macular degeneration.” When he saw my face fall, he added: “AMD – it’s very common.” My grandmother suffered.